CDK4/6 Inhibition for Dedifferentiated Liposarcoma Tumor Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dedifferentiated liposarcoma, particularly chemotherapeutic options, are limited in efficacy and response, necessitating the development of a more effective drug to manage this aggressive sarcoma.
Innovation Solution
The use of a CDK4/6 inhibitor, specifically a substituted 2-hydrogen-pyrazole derivative, to inhibit the progression of the cell cycle and halt tumor proliferation in dedifferentiated liposarcoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first-line chemotherapeutic drugs are used for dedifferentiated liposarcoma, then treatment is provided, but the tumor responds poorly and efficacy is limited
Solution Approach 1:
The patent applies parameter changes by switching from conventional chemotherapeutic drugs to a CDK4/6 inhibitor (a different drug class with different mechanism of action). This changes the therapeutic parameter from traditional chemotherapy to targeted cell cycle inhibition, thereby overcoming the poor response to first-line chemotherapeutic drugs and improving treatment efficacy for dedifferentiated liposarcoma
2Reliability
If radical surgical resection is used for dedifferentiated liposarcoma, then local control is improved, but the overall survival rate is not influenced and local recurrence remains high
Solution Approach 1:
The patent applies preliminary action by using the CDK4/6 inhibitor as neoadjuvant therapy before surgical resection. This preliminary pharmacological treatment reduces tumor burden and improves tumor characteristics prior to surgery, thereby enhancing both local control and potentially improving overall survival outcomes that surgery alone cannot achieve
3Adaptability or versatility
If conventional chemotherapy is used for dedifferentiated liposarcoma, then treatment options are provided, but the response rate is poor and recurrence is high
Solution Approach 1:
The patent introduces an intermediary mechanism by using CDK4/6 inhibition as a mediator between conventional chemotherapy and surgical treatment. This targeted inhibitor acts as an intermediate therapeutic approach that addresses the poor response to chemotherapy while preparing for surgery, thereby improving disease control and reducing recurrence
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CDK4/6 inhibitor demonstrates good tumor growth reduction, well-tolerated treatment with minimal adverse effects, improved disease control, prolonged progression-free and overall survival, and increased objective response rates in patients with dedifferentiated liposarcoma.
Implementation Method 1
Cyclin-dependent kinase (CDK) 4/6 is a key regulator of the cell cycle and is capable of triggering the progression of the cell cycle from the growth phase (G1 phase) to the DNA replication phase (S1 phase)... the inhibition of CDK4/6 makes it unable to form a cyclin D-CDK4/6 complex, which can block the progression of the cell cycle from the G1 phase to the S phase
Implementation Method 2
the complex formed by CDK4/6 and cyclin D can phosphorylate the retinoblastoma protein (Rb). Once the tumor suppressor protein Rb is phosphorylated, it can release transcription factor E2F
Data Source
AI summary
A CDK4/6 inhibitor for use in treatment of dedifferentiated liposarcoma, in particular to the use of a compound of formula (I) in treatment of dedifferentiated liposarcoma.